Skip to main content

Table 2 Prognostic Factors for Local Tumor Progression (LTP) after RFA

From: Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance

Factor All patients without LTP (N = 189, %) All patients with LTP
(N = 40, %)
Univariable Analysis Multivariable Analysis
Hazard Ratio(95%CI) P value Hazard Ratio(95%CI) P value
Child-Pugh class 0.783
 A 174 (92.1) 36 (90.0) 1 (Reference) 0.512 1(Reference)
 B 15 (7.9) 4 (10.0) 1.416 (0.501–4.004)   1.163 (0.397–3.408)
Etiology of tumor
 Hepatitis B virus 148 (78.3) 28 (70.0) 0.682 (0.238–1.953) 0.476 0.703 (0.228–2.170) 0.540
 Hepatitis C virus 16 (8.5) 5 (12.5) 1.214 (0.324–4.548)   1.145 (0.271–4.834) 0.853
 Non-B, non-C hepatitis 8 (4.2) 3 (7.5) 1.513 (0.337–6.795) 0.774 3.141 (0.626–15.749) 0.164
 No 17 (9.0) 4 (10.0) 1 (Reference) 0.589 1 (Reference)
AFP (ng/ml)  
  ≤ 20 115 (60.8) 23 (57.5) 1 (Reference)   1 (Reference)
 >20 and<400 55 (29.1) 8 (20.0) 0.881 (0.394–1.970) 0.757 1.133 (0.490–2.616) 0.770
  ≥ 400 19 (10.1) 9 (22.5) 2.466 (1.090–5.576) 0.030 2.431 (1.000–5.907) 0.050
 Tumor size (cm) 2.67 ± 1.13 3.24 ± 1.10 1.529 (1.172–1.994) 0.002 1.553 (1.151–2.095) 0.004
TACE before RFA 0.770
 Yes 122 (64.6) 28 (70.0) 1.216 (0.616–2.401) 0.573 0.898 (0.436–1.849)
 No 67 (35.4) 12 (30.0) 1 (Reference)   1 (Reference)
Classification of HCC 0.024
 Periportal HCC 37 (19.6) 15 (37.5) 2.370 (1.242–4.521) 0.009 2.200 (1.111–4.358)
 Nonperiportal HCC 152 (80.4) 25 (62.5) 1 (Reference)   1 (Reference)